US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Ophthalmology Market Research Reports & Industry Analysis

A portion of ophthalmology that resists change unlike some other specialties is the consumer reluctance to undertake a procedure that may have side effects associated with vision like refractive laser correction. Any side effects concerning eyes/vision is typically avoided as much as possible especially if there are other options.
Typically if the out-of pocket price for a life-enhancing procedure is within the budget of a consumer, the patient has a strong desire to get the procedure, and other factors are present that allow for it, the procedure is undertaken. In laser correction there has been skepticism which has diminished as more patients undertake the procedure with good results. While new ideas, breakthrough technologies, cost efficiencies, increased productivity,and new markets are the keys to growth and competitiveness, most people [work force; consumers; academics; politicians] are more confident in familiar environments. They will resist change unless their job, livelihood, or lifestyles are threatened.

This phenomenon is partly responsible for the trend toward closing solo and small group practices to join vision care networks. Though this experience exists more in general medical practices and some pecialties, ophthalmologists also face the threat of practitioners [osteopathic physicians, doctors of optometry] replacing eye MDs—an intrusion on their medical training, skills, and specialty. However increasing healthcare costs, and economic changes sometimes force shifts in the typical work pattern of healthcare providers. One example is a change that has happened in states across the U.S. allowing optometrists to diagnose and treat glaucoma.

RSS Feeds

Ophthalmology Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
Ophthalmologists: State Industry Market Evaluator 621111.07
12/1/2014 | published by: BizMiner
... for 2011-2012-2013-2014q2 for these measures: industry market volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, ...  |  read more...
USD 599
Offices of Optometrists: State Industry Market Evaluator 621320
12/1/2014 | published by: BizMiner
... are displayed for 2011-2012-2013-2014q2 for these measures: industry market volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure ...  |  read more...
USD 599
Retinal Degeneration - Pipeline Review, H2 2014
12/10/2014 | published by: Global Markets Direct
... therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014
11/30/2014 | published by: Global Markets Direct
... Exudative) Macular Degeneration’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of ...  |  read more...
USD 2,000
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2014
11/30/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Ocular Inflammation Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Wet (Neovascular / Exudative) Macular Degeneration Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and ...  |  read more...
USD 2,000
Ocular Inflammation-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Ocular Inflammation. This report provides information on the therapeutic development based on the Ocular Inflammation dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Ocular Pain-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Ocular Pain. This report provides information on the therapeutic development based on the Ocular Pain dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Eye Infections-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Eye Infections. This report provides information on the therapeutic development based on the Eye Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Cataract - Pipeline Review, H2 2014
11/14/2014 | published by: Global Markets Direct
... Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Eye Infections-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Glaucoma-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Ocular Pain-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. ...  |  read more...
USD 2,000
Open-Angle Glaucoma Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Herpes Zoster Ophthalmicus Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the ...  |  read more...
USD 2,000
Ocular Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and ...  |  read more...
USD 2,000
Eye Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Ocular Hypertension Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Juvenile Macular Degeneration (Stargardt Disease)-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... establish the understanding for all the pipeline drugs that fall under Juvenile Macular Degeneration (Stargardt Disease). This report provides information on the therapeutic development based on the Juvenile Macular Degeneration (Stargardt Disease) dealing with all ...  |  read more...
USD 1,250
Ocular Hypertension-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Ocular Hypertension. This report provides information on the therapeutic development based on the Ocular Hypertension dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Open-Angle Glaucoma-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Open-Angle Glaucoma. This report provides information on the therapeutic development based on the Open-Angle Glaucoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2014
11/14/2014 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Age-related Macular Degeneration Partnering 2009-2014
11/1/2014 | published by: Current Partnering
... age-related macular degeneration partnering deals Top age-related macular degeneration deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Age-related Macular Degeneration Partnering 2009-2014 provides understanding and access to the ...  |  read more...
USD 695
< prev 1    3  4  5  6  7  8  9  10